secwatch.observer — SEC 8-K summary
======================================

Issuer:     Summit Therapeutics Inc. (SMMT)
CIK:        0001599298
Form:       8-K
Filed at:   2026-09-29T01:39:22+00:00
Accession:  0001193125-26-405776
Event type: m_and_a
Sentiment:  positive
Materiality: 0.88
Item codes: 1.01, 5.03, 3.02, 8.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

AstraZeneca to invest $2B in Summit at $18.36/share, a 10% premium, plus clinical collaboration
--------------------------------------------------------------------------------

- AstraZeneca Holdings B.V. buys 108,955.3686 Class A Convertible Preferred shares at $18,356.14 each for $2.0B; each converts into 1,000 common shares.
- Effective common price of $18.36 equals VWAP of the five trading days from the prior week plus 10%, a premium to Summit's closing price; closing expected by end of this week.
- Conversion is blocked until the HSR waiting period ends and a charter amendment authorizing enough common shares is effective; Summit must redeem for cash if the amendment misses an 18-month deadline.
- Summit also signed a clinical collaboration with AstraZeneca to test sonesitatug vedotin (sone-ve) plus ivonescimab in gastrointestinal cancers, AstraZeneca-sponsored with shared costs.
- A non-binding MOU covers combining ivonescimab with AstraZeneca's ADC portfolio; no milestones, royalties, revenue-sharing or profit-sharing; resale registration due within 60 days of closing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1599298/000119312526405776/0001193125-26-405776-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1599298/000119312526405776/d178892d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-405776

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer